Menu

Investors

SEC Filings

SEC Filings

Filing date Form Description View
May 12, 2026 SCHEDULE 13G SCHEDULE 13G - Description View HTML
May 7, 2026 8-K Report of unscheduled material events or corporate event EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA View HTML
May 7, 2026 10-Q Quarterly report which provides a continuing view of a company's financial position EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA View HTML
April 29, 2026 ARS An annual report to security holders View HTML
April 28, 2026 DEFA14A Additional proxy soliciting materials - definitive View HTML
April 28, 2026 DEF 14A Official notification to shareholders of matters to be brought to a vote ("Proxy") EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA View HTML
April 15, 2026 PRE 14A A preliminary proxy statement providing notification matters to be brought to a vote EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA View HTML
April 3, 2026 3 Initial filing by director officer or owner of more than ten percent View HTML
April 3, 2026 4 Statement of changes in beneficial ownership of securities View HTML
April 1, 2026 8-K Report of unscheduled material events or corporate event EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA View HTML

Data provided by Kaleidoscope.

Print Page
Email Page
Contact IR
Email Alerts
Tear Sheet

Akebia Therapeutics, Inc.
245 First Street, Suite 1400
Cambridge, MA 02142

Driving Directions

+1 617.871.2098  phone
+1 617.871.2099  fax

Contact Us